Wing Shan Cheung

US Patent:

6696056, Feb 24, 2004

Filed:

Apr 7, 2000

Appl. No.:

09/545479

Inventors:

Wing K. Cheung - Warren NJ
Jaya Natarajan - Hillsborough NJ
Marilyn Sanders - Raritan NJ
Els Vercammen - Dietlikon, CH
Selima Begum - Edison NJ
Basant Sharma - Bridgewater NJ

Assignee:

Ortho McNeil Pharmaceutical, Inc. - Raritan NJ

International Classification:

A61K 3819

US Classification:

424 851, 514 8, 514 21

Abstract:

The present invention provides aqueous pharmaceutical formulations of erythropoietin that are free of human serum blood products, stabilized with a quantity of an amino acid and a sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivative. The present invention also provides aqueous stable, preserved pharmaceutical formulations of erythropoietin that contain an antimicrobial quantity of cresol and a quantity of an amino acid.

US Patent:

6747002, Jun 8, 2004

Filed:

May 10, 2000

Appl. No.:

09/569612

Inventors:

Wing Cheung - Warren NJ
David Gibson - Bassersdorf, CH
Christine Cote - Skillman NJ
Els Vercammen - Dietlikon, CH

Assignee:

Ortho-McNeil Pharmaceutical, Inc. - Raritan NJ

International Classification:

A61K 3819

US Classification:

514 8, 530351

Abstract:

The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.

US Patent:

20040157778, Aug 12, 2004

Filed:

Mar 24, 2004

Appl. No.:

10/807429

Inventors:

Wing Cheung - Warren NJ, US
David Gibson - Basserdorf, CH
Christine Cote - Skillman NJ, US
Els Vercammen - Dietlikon, CH

International Classification:

A61K038/18

US Classification:

514/012000

Abstract:

The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.

US Patent:

20040176297, Sep 9, 2004

Filed:

Mar 24, 2004

Appl. No.:

10/807451

Inventors:

Wing Cheung - Warren NJ, US
David Gibson - Bassersdorf, CH
Christine Cote - Skillman NJ, US
Els Vercammen - Dietlikon, CH

International Classification:

A61K038/18
G01N033/48
G01N033/50
A61K033/24

US Classification:

514/012000, 424/649000, 702/019000

Abstract:

The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.

US Patent:

20040248797, Dec 9, 2004

Filed:

Feb 10, 2004

Appl. No.:

10/775928

Inventors:

Wing Cheung - Warren NJ, US
Jaya Natarajan - Hillsborough NJ, US
Marilyn Sanders - Raritan NJ, US
Els Vercammen - Oxfordshire, GB
Selima Begum - Edison NJ, US
Basant Sharma - Bridgewater NJ, US

Assignee:

Ortho McNeil Pharmaceutical, Inc.

International Classification:

A61K038/18

US Classification:

514/012000

Abstract:

The present invention provides aqueous pharmaceutical formulations of erytropoietin that are free of human serum blood products, stabilized with a quantity of an amino acid and a sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivative. The present invention also provides aqueous stable, preserved pharmaceutical formulations of erythropoietin that contain an antimicrobial quantity of cresol and a quantity of an amino acid.

US Patent:

20050267026, Dec 1, 2005

Filed:

Mar 24, 2005

Appl. No.:

11/088284

Inventors:

Wing Cheung - Warren NJ, US

International Classification:

A61K038/18

US Classification:

514012000

Abstract:

The present invention provides a combination dosing regimen for erythropoietin (EPO). More particularly, the present dosing regimen includes administration of at least a first dosing segment comprising a first exposure to EPO capable of stimulating the production of reticulocytes followed by a second exposure to EPO capable of sustaining the maturation of the reticulocytes into neocytes, and ultimately, red blood cells. Advantageously, the dosing segment may be cycled or repeated, any number of times and according to any desired time scheme, in order to provide or maintain any desired total red blood cell count and/or hemoglobin concentration. Methods of treatment employing the combination dosing regimen, as well as kits are also provided.

US Patent:

20060100150, May 11, 2006

Filed:

Dec 15, 2005

Appl. No.:

11/304721

Inventors:

Wing Cheung - Warren NJ, US
David Gibson - Bassersdorf, CH
Christine Cote - Skillman NJ, US
Els Vercammen - Dietlikon, CH

International Classification:

A61K 38/18
G06F 19/00

US Classification:

514012000, 702019000

Abstract:

The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.

US Patent:

20060128624, Jun 15, 2006

Filed:

Jan 24, 2006

Appl. No.:

11/338500

Inventors:

Wing Cheung - Warren NJ, US
David Gibson - Basserdorf, CH
Christine Cote - Skillman NJ, US
Els Vercammen - Dietlikon, CH

International Classification:

A61K 38/18
G06F 19/00

US Classification:

514012000, 702019000

Abstract:

The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.